In a new study, researchers from the Indiana Center for Regenerative Medicine and Engineering (ICRME) identified a new type of cells, angiogenic fibroblasts (vasculogenic fibroblast), in humans and mice, providing important insights into how to create new blood vessels when needed. The results were published in the Nature Communications journal on February 28,2023 with the title "Identification of a physiologic vasculogenic fibroblast state to achieve tissue repair".
Blood vessels are formed by endothelial cells, but these authors found that angiogenic fibroblasts can also make new blood vessels and achieve blood flow. Dr. Chandan K Sen, corresponding author of the paper and director of the Indiana Regenerative Medicine and Engineering Center, said, " Ischemic disease is common and limited by poor blood supply- - - -diabetic wounds are one of them. Growing blood vessels to treat ischemic disease, preventing blood vessel growth to limit tumor growth, requires a complete understanding of how blood vessels form in the body. The discovery of angiogenic fibroblasts uncovered a critical part of the mystery that helps to achieve targeted therapies.”
These individuals observed angiogenic fibroblasts from human patients. When someone is injured, the body begins to produce angiogenic fibroblasts, which form new blood vessels to heal the damaged tissue. But in some patients, such as with diabetes, the ability to make such special cells is diminished. In laboratory models, Sen and his team used their tissue nanotransfection (tissue nanotransfection, TNT) technology for tissue reprogramming to replenish angiogenic fibroblasts in tissues affected by diabetes. This has led to improvements in blood flow and improved diabetic wound closure.
Sen, " This new study not only identifies a cell that has been working silently in the body, but we can use TNT and angiogenic tissue reprogramming to make these cells and rescue tissues adversely affected by blood supply.”。
TNT and regenerative medicine is an evolving industry around the world and in Indiana that seeks to replace or regenerate human somatic cells, tissues, and organs. According to MarketWatch, the TNT market is worth $2.07 billion in 2020 and is expected to grow to $7.06 billion by 2028, due to increased dermatology, chronic disease and trauma emergencies, and increased awareness of successful organizational engineering projects.
Sen said, " In less than a second, a TNT nanochip simply delivers an antisense oligonucleotide to the skin to convert skin fibroblasts into angiogenic fibroblasts. This innovative technology continues to show promise in providing simple and effective treatments for many different health problems in many different situations."
